Influence of enteral formula containing EPA/DHA on inflammation and iron metabolism in tube-fed elderly patients

Influence of enteral formula containing EPA/DHA on inflammation and iron metabolism in tube-fed elderly patients - Influence of enteral formula containing EPA/DHA on inflammation

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000010990

Enrollment

Registered

2013-06-18

Start date

2010-06-18

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

chronic inflammation, abnormal iron metabolism

Interventions

Administration of enteral formula containing EPA/DHA for 8 weeks, while maintaining the total energy intake.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Bedridden elderly patients receiving total enteral nutrition, who are stable.

Exclusion criteria

Exclusion criteria: 1)Patients receiving enteral formula containing EPA/DHA. 2)Patients with hepatic, renal, cardiovascular, respiratory and intestinal dysfunction, persistent infection and malignancy. 3)Patients with allergy to milk, soybean and fish oil, which are contained in the enteral formula. 4)Patients judged as inappropriate for the study by the physician in charge.

Design outcomes

Primary

Measure	Time frame
hs-CRP, IL-6, TNF-alpha, hepcidin, serum iron, ferritin, total iron-binding capacity, transferrin, hemoglobin	—

Secondary

Measure	Time frame
EPA, DHA, EPA/AA ratio, triglyceride, total cholesterol, LDL-cholesterol, HDL-cholesterol, adiponectin, leptin, MCP-1, resistin	—

Countries

Japan

Contacts

Public ContactHiroyasu Akatsu

Fukushimura Hospital Choju Medical Institute

0532-46-7511

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026